Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood

Matthew J. Matasar(Rutgers, The State University of New Jersey), David J. Straus(Memorial Sloan Kettering Cancer Center)

JNCI Journal of the National Cancer Institute

February 24, 2015

10.1093/jnci/djv018

Cited by 45

Related Papers

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

|The Lancet Oncology|2022|429

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

|Blood|2001|427

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

|Cancer|2003|151

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

|Cancer Cell|2022|88

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

|Blood|2024|28